Literature DB >> 688244

Combination chemotherapy for ovarian carcinoma with cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum(II) after failure of initial chemotherapy.

H W Bruckner, L H Ratner, C J Cohen, R Wallach, B Kabakow, E M Greenspan, J F Holland.   

Abstract

Twenty-four patients who had stage III or IV ovarian adenocarcinoma and had failed prior chemotherapy were treated with cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum(II) every 3 weeks. Twelve patients had objective responses and an additional six had subjective improvement. The median duration of survival for responders is 9 months. There were no instances of nephrotoxicity. Fluid management consisted of 1000-2000 ml of iv fluid without Lasix- or mannitol-induced diuresis. Patients responded after having failed radiotherapy or multiple-drug chemotherapy, including some who were 70-75 years of age or were greater than 50% bedridden. Patients with one- or two-drug prior chemotherapy had a higher response rate (ten responses among 17 patients) than those previously treated with three or more drugs (two responses among seven patients).

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 688244

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  5 in total

Review 1.  Chemotherapy in the management of ovarian carcinoma: a review.

Authors:  J S Malpas
Journal:  J R Soc Med       Date:  1979-05       Impact factor: 5.344

Review 2.  Cis-platinum: a new anticancer agent.

Authors:  C J Williams; J M Whitehouse
Journal:  Br Med J       Date:  1979-06-23

3.  Cisplatin, adriamycin and cyclophosphamide (PACe) combination chemotherapy in patients with ovarian carcinoma resistant to chlorambucil.

Authors:  G M Mead; C J Williams; J M Whitehouse
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Individual chemosensitivity of in vitro proliferating mammary and ovarian carcinoma cells in comparison to clinical results of chemotherapy.

Authors:  M Albrecht; W E Simon; F Hölzel
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

5.  cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma.

Authors:  J Carmo-Pereira; F O Costa; E Henriques
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.